Effect of mazindol on dystrophic mice and on growth in young rats

1. Mazindol, which has been proposed as a therapy for muscular dystrophy because of a suppression of growth hormone release was administered orally (0.1 mg/kg body wt/day) for approximately six weeks to healthy young rats and dystrophic mice. 2. Mazindol had no effect on the dystrophic mice. 3. Mazindol treated rats had reduced wt gain, but this effect was due to appetite suppression not growth hormone inhibition. 4. No effect of mazindol was seen on rat muscle, but there were significant increases in liver, heart and kidney wts compared to controls.     

Dopaminergic and serotoninergic anorectics differentially antagonize insulin- and 2-DG-induced hyperphagia

The efficacy of anorectic drugs has been studied in rats made hyperphagic by injection of insulin or of 2-deoxy-d-glucose (2-DG). It was found that anorectics that act through a serotoninergic mechanism, i.e., d- and d-l-fenfluramine, p-chloroamphetamine, quipazine and fluoxetine antagonize both insulin- and 2-DG-induced overeating, while anorectics acting through the dopaminergic system, i.e., d-amphetamine, diethylpropion, lisuride, bromocriptine and mazindol, antagonize the hyperphagia induced by 2-DG but not that induced by insulin. Neither serotoninergic nor dopaminergic anorectics modified insulin-induced hypoglycaemia. The serotonin (5-HT) receptor blocker metergoline did not modify the hyperphagic response to insulin or 2-DG. The present results indicate that there are different neuronal or humoral circuits underlying the hyperphagic responses to insulin and 2-DG. In addition, these results, which show different effectiveness of anorectic drugs depending on what has provoked the hyperphagia, suggest that differences in the etiology of the hyperphagia of obese subjects must be taken into consideration when choosing therapy.     

Changes in thermogenesis and brown fat activity in response to tumour necrosis factor in the rat

A single intravenous injection of recombinant human tumour necrosis factor (TNF) resulted in significant, but transient (24–48 hr) reductions in food intake and body weight, and increases in rectal temperature, resting oxygen consumption (VO₂) and brown adipose tissue (BAT) thermogenic activity (mitochondrial GDP-binding). The increased VO₂ was inhibited by -adrenergic blockade (propranolol), and activation of BAT was prevented by denervation of the tissue. In adult (4-month old) animals, TNF induced greater reductions in food intake and body weight, caused general malaise and some fatalities, but did not significantly alter VO₂ or BAT activity. However, the reduction in VO₂ following -adrenergic blockade was greater in TNF-treated rats and BAT activity was enhanced when compared to pair-fed controls. Injection of adult rats with gamma-interferon induced small changes in body weight and temperature which were slightly potentiated when injected with a low dose of TNF. The results indicate that TNF stimulates sympathetic outflow to BAT. This effect may be partly responsible for the increases in body temperature and metabolic rate associated with TNF treatment and with cancer cachexia.     

Further evidence of the inhibitory role of perifornical hypothalamic beta-adrenergic receptors in the feeding behaviour of hungry rats

The reduction of food intake in hungry rats induced by salbutamol (10 mg/kg/i.p.) was prevented by IPS 339 (5 mg/kg, i.p.) a selective beta 2 adrenergic antagonist, but not by metoprolol (10 mg/kg i.p.), a blocker of beta 1 adrenergic receptors. Similarly, bilateral injections of IPS 339 (32 micrograms/1 microliter) but not metoprolol (80 micrograms/1 microliter) in the perifornical hypothalamic area completely antagonized the anorectic effect of intraperitoneal salbutamol, suggesting an involvement of beta 2 adrenergic receptors in this brain area. Clenbuterol, a beta 2 adrenergic agonist which readily crosses the blood-brain barrier, was 10-100 times more potent than salbutamol in inhibiting feeding consumption of deprived rats when injected intraperitoneally and this effect was also selectively antagonized by pretreatment with IPS 339. Neither IPS 339 nor metoprolol injected in the perifornical hypothalamus significantly modified the anorectic effect of diethylpropion (5 mg/kg i.p.) whereas it was partially prevented by intraperifornical injection of 1-propranolol (52 micrograms/2 microliter), a non-selective beta antagonist, suggesting that both beta 1 and beta 2 adrenergic receptors in the hypothalamus contribute to the mechanism by which diethylpropion causes anorexia.     

Physiological responses of naloxone-treated pigeons to changes in ambient temperature

1. In pigeons given single intramuscular injection of naloxone, the heart rate (HR), breathing frequency (BF), oxygen consumption (VO₂), cloacal temperature (T_c) and foot temperature (T_f) were monitored during gradual lowering of the ambient temperature (T,) from 34°C to 6° in 6 hr.2. The two doses of naloxone tested (2 mg and 5 mg/kg b.w.) had an inhibitory effect on HR, the effect being greater with the higher dose as well as with the fall in T_a.3. The higher dose showed a tendency to have a stimulatory effect on BF in T_a above 22°C and an inhibitory effect in T_a below 22°C. With the lower dose, BF remained unaltered except in T_a below 12°C during which it showed a trend toward a decrease.4. VO₂ decreased with the higher dose, the extent of decrease being greater with drop in T_a. With the lower dose, VO₂ was not affected at or below T_a 26°C, but showed a trend toward an increase at T_a above 26°.5. The higher dose produced hyperthermia when T_a was below 14°C, whereas with the lower dose, T_c showed no significant change except for a slight drop at T_a 6°C.6. T_fwas not significantly affected by naloxone treatment.7. It is suggested that these effects were caused by the inhibition of endorphine-mediated catecholamine release by naloxone.     

Effect of mazindol administration on (3H)-N-methylscopolamine binding to rat cerebral cortex.

Mazindol has been shown to produce anorexia in several animal species including humans, and its pharmacological effects may be elicited by blockade of neuronal reuptake of dopamine and norepinephrine. Chronic treatment of rats with mazindol (10 mg/kg daily, p.o.) caused an increase in muscarinic receptor density (Bmax = 874.7 femtomoles/mg protein) as compared to controls (Bmax = 629.1 femtomoles/mg protein) in the cerebral motor cortex. An increase in dissociation constant (Kd) values was also observed which changes from 0.57 nM (control) to 1.17 nM after mazindol treatment. The mechanism underlying the observed effect of mazindol on receptors could be related to processes involving other neurotransmitters which also regulate cholinergic activity in the CNS. However, the implications of the eventual dopaminergic control on muscarinic receptors in the cortex is still an open question.     

Characterization of [3H]Mazindol Binding in Rat Brain: Sodium-Sensitive Binding Correlates with the Anorectic Potencies of Phenylethylamines

Saturable low-affinity binding sites for [3H]mazindol have been demonstrated in crude synaptosomal membranes from rat brain using both a centrifugation and a filtion assay. Studies on the regional distribution of these binding sites revealed that the hypothalamus and brainstem had the highest density of sites. Kinetic analysis of the binding of [3H]mazindol to hypothalamic membranes demonstrated a single class of noninteracting binding sites with an apparent affinity constant (KD) of 10.2 +/- 0.7 microM and maximal number of binding sites (Bmax) of 786 +/- 94 pmol/mg of protein. Specific [3H]mazindol binding was rapidly reversible, temperature sensitive, labile to pretreatment with proteolytic enzymes, and inhibited by physiological concentrations of sodium. In most peripheral tissues, such as the liver and kidney, very low levels of binding were observed; however, the adrenal gland had a relatively high density of sites. The potency of a series of anorectic drugs in inhibiting specific [3H]mazindol binding to hypothalamic membranes was highly correlated with their anorectic potencies in rats, but not with their motor stimulatory effects. These results suggest the presence of a specific drug recognition site in the hypothalamus that may mediate the anorectic activity of mazindol and related phenylethylamines.     

The possibility of peripheral cholinolytic action of psychostimulants

The cholinolytic effect of sydnophen discovered in earlier anesthetized cats was confirmed on unanesthetized fish and frogs: the vagal bradycardia induced by electric stimulation of peripheral vagal end was decreased or even abolished by intravenous injection of sydnophen (0.2-20 mg/kg). The amphetamine (0.2-30 mg/kg) also blocked the vagal bradycardia in anesthetized cats and unanesthetized frogs. The maximum vagolytic action of amphetamine appeared later (in 4-8 min after injection) in compared with sydnophen (1-3 min). The small dose of amphetamine (0.2-0.3 mg/kg) in contrast to sydnophen didn't decrease the vagal bradycardia but even increased it. It was suggested that the cholinolytic effect of sydnophen and amphetamine is due to different mechanisms.     

Effects of dopaminergic and cholinergic interactions on rat behavior.

The present work studied the effects of dopaminergic and muscarinic receptor agonists and antagonists on rat locomotor activity and catalepsy. Results showed that carbachol at the highest dose used (10 mg/kg, p.o.) decreased and pimozide at the dose used abolished locomotor activity. Atropine at a low dose (1 mg/kg, p.o.) increased and at a high dose decreased this parameter. Mazindol at a high dose also increased locomotor activity. A significant and dose-dependent increase in the time on the bar was observed in animals treated with carbachol or pimozide as compared to controls. The increase observed with pimozide was greater than 60 s. Effects of carbachol on locomotor activity were observed already after the first drug exposure, but the increased time on bar produced by this drug in the test of catalepsy was observed only after repeated exposure (7th day). The effect of the highest dose (10 mg/kg, p.o.) of atropine (decreased activity) as related to the lowest one was evident at the 7th day, but the increased locomotor activity seen at the low dose was detected already at the first day. There was a predominance of the effect of pimozide on the open field as well as on catalepsy after its association with each one of the three doses of carbachol. The association of atropine and mazindol did not seem to alter locomotor activity and catalepsy as related to each drug alone. Our results indicate that interactions between dopaminergic and cholinergic systems play an important role on behavior and motor functions.     

Effects of inhibitors of thromboxane synthesis on reactions of the cat bronchus in situ to prostaglandins

Cats were anesthetized by chloralose, relaxed by suxamethonium, and ventilated. The influence of 3 inhibitors of thromboxane synthesis, N.0096 (±α-benzyl-α-p-chlorobenzyl-4-hydroxyacetophenon phenylhydrogen-phosphonate), imidazole and dipyridamole were studied on bronchial reactions to prostaglandins E₂ and F₂α and arachidonic acid. During a bronchoconstriction maintained by infusion of 5-HT, N.0096 and imidazole dose-dependently potentiated the intensity and duration of the bronchodilator effect of PGE₂. This effect was maximal at a total dose of 17 mg/kg N.0096 or 25–50 mg/kg imidazole, but decreased after higher doses which are supposed to inhibit cyclo-oxygenase also. Bronchoconstrictor reactions to single injections of arachidonic acid were inhibited by N.0096 in the same dose range. Reactions to PGF_2α were unaltered by both drugs. Dipyridamole was devoid of a comparable activity.     

The orally active thia-imino-prostacyclin Hoe 892: Antiaggregatory and cardiovascular activities

The short chemical half-life limits the potential therapeutic value of Prostacyclin (PGI₂). Replacement of the acid-labile enolether structure of PGI₂ by a β-thia-imino group resulted in the orally active and chemically stable analogue Hoe 892. Incubation of rabbit platelet rich plasma with PGI₂ and Hoe 892 caused a dose dependent inhibition of collagen and arachidonic acid (AA) induced platelet aggregation with ID₅₀ of 4.2 and 20.1 ng/ml for PGI₂ respectively 43.3 and 170.2 ng/ml for Hoe 892. These effects could be potentiated by the phosphodiesterase inhibitor theophylline. Single oral administration of Hoe 892 in conscious rabbits inhibited platelet aggregation for more than 3 hrs with an ID₅₀ of 0.2 mg/kg using collagen and 1.5 mg/kg using AA. These doses were without influence on systemic blood pressure (BP) in conscious rabbits. One month oral treatment with a daily dose of 0.3 mg/kg resulted in marked antiaggregatory effects in conscious rabbits. Intravenous injection of Hoe 892 induced a dose dependent decrease of systemic BP in anesthetized rats (ED₂₅ of 2.2 μg/kg) and in the rats with acute renal hypertension. Hoe 892 stimulated renin release in anesthetized rats. The hemodynamic profile in anesthetized dogs (0.5 μg/kg/min i.v.) was characterized by a decrease of systemic BP, left ventricular pressure, pulmonary artery pressure, total peripheral resistance and in increase in heart rate, cardiac output and dp/dt max, thus demonstrating arteriolar vasodilation. In conscious dogs with two kidney, two wrapped hypertension oral treatment for 1 or 5 days resulted in a marked reduction of BP.     

Evidence against prostaglandin modulation of cardioaccelerator nerve activity in the anesthetized dog

The hypothesis that prostaglandins have a modulatory role in adrenergic neurotransmitter release was tested in the anesthetized dog. Inhibition of prostaglandin synthesis with indomethacin (10 mg/kg, i.v.) did not alter positive chronotropic responses to cardioaccelerator nerve stimulation or blood pressure responses to exogenous norepinephrine. In the presence of indomethacin, infusions of PGE₂ (0.01 and 0.1 μg kg⁻¹ min⁻¹) also failed to influence the responses to cardioaccelerator nerve stimulation although the blood pressure responses to exogenous norepinephrine were reduced in a dose-related manner. It was concluded that endogenous prostaglandins and exogenous PGE₂, the purported physiological inhibitor of neurotransmitter release in cardiac tissue, do not play a role in modulating chronotropic responses during cardioaccelerator nerve stimulation in the anesthetized dog.     

The occurrence of cross-tolerance between morphine and ethyl-ketocyclazocine using the tail-flick test: Lack of effect of diazepam,phenobarbital, or amphetamine

Experiments were designed to test for short-term tolerance to morphine and ethyl-ketocyclazocine (EKC), mu and kappa agonists, respectively, and cross-tolerance between the two drugs. Mice were primed with one of the drugs, using doses that did not affect the tail-flick response when tested at a time 1 or 3 hours later, when the same or alternate test drug was administered. All animals were injected with the priming drug IP. In one series of experiments, the test drugs were given SC, and in the other, the test drugs were injected ICV under brief halothane anesthesia. Priming with morphine (30 or 100 mg/kg) significantly raised the ED₅₀ for ICV morphine. Priming with EKC (2 or 6 mg/kg) similarly elevated the ED₅₀'s for SC and ICV EKC. Symmetrical cross-tolerance was produced in experiments where the test drugs were administered SC when tested at 3 hrs. The effects of priming with EKC on morphine analgesia was evident when the interval between priming and test drugs was 1 hour. When the test drugs were given ICV, cross-tolerance was also symmetrical: priming with EKC significantly raised the ED₅₀ for morphine and priming with morphine raised the ED₅₀ for EKC when tested at 3 hrs. These data suggest that both agonists act on a common site to produce analgesia as similar pA₂ values for naloxone antagonism were determined. The occurrence of short-term tolerance and cross-tolerance to the opiates was unaltered by chronic pretreatment with diazepam, phenobarbital, or amphetamine.     

The effect of phenobarbital on chlorphentermine-induced lipidosis-like alterations in renal tissue of adult and newborn rats

Daily oral administration of 20 or 60 mg/kg chlorphentermine for 1 week produced a dose-related increase in the number of myeloid bodies in renal tissue of both adult and newborn rats. In adults myeloid bodies were present throughout the kidney while in neonates these bodies were found predominantly in the medullary region. Simultaneous administration of phenobarbital and either chlorphentermine dose resulted in a reduction in the number of myeloid bodies in kidneys of adults and newborns. Our data show that phenobarbital prevented the chlorphentermine-induced lipidosis in renal tissue and that newborns appear less sensitive than adults to the histopathologic action of anorectic on kidney.     

Central effects of TNFα on thermogenesis and fever in the rat

Intracerebroventricular (icv) injection of purified recombinant human tumour necrosis factor (TNF , 4–8g) in conscious rats, produced increases in colonic temperature (1.0°C) and resting oxygen consumption (VO₂, 14%) which were maximal after 80–90 minutes. Pretreatment with propranolol (10mg/kg s.c) significantly inhibited the rise in VO₂, and prevented the increase in body temperature. Icv injection of an antagonist to corticotropin releasing factor (-helical CRF 9-41, 25 g), which prevents the pyrogenic and thermogenic actions of interleukin-1, did not influence the effects of TNF on temperature or VO₂. Injection of a fragment of TNF (113–130 amino acid sequence) did not affect body temperature or VO₂. TNF injection (icv) significantly increased brown adipose tissue (BAT)in vitro mitochondrial GDP binding, and this effect was slightly inhibited, but not prevented, by surgical denervation of the tissue, and was unaffected by pretreatment with -helical CRF 9-41. These data indicate that TNF can stimulate thermogenesis by a direct central action. The effects are largely, but not totally, dependent on the sympathetic nervous system but, unlike the thermogenic actions of interleukin they do not require release of CRF.     

Effect of indomethacin, tiaprofenic acid and dicrofenac on rat gastric mucosal damage and content of prostacyclin and prostaglandin E2

Gastric ulcerogenicity and depletion of endogenous prostaglandins (PGs) content induced by tiaprofenic acid, dicrofenac and indomethacin were examined using the same antiinflammatory effective doses. Male Wistar rats were given each of these drugs intragasrically 24, 18, and 3 hrs before sacrifice in the following doses (mg/kg): indomethacin (0.8, 4 and 20); tiaprofenic acid (1.2, 6 and 30); dicrofenac (0.8, 4 and 20). Endogenous prostacyclin (PGI₂) and PGE₂ in fundic mucosa were determined by radioimmunoassay. The three compounds produced fundic mucosal lesions in a dose-dependent manner. However, tiaprofenic acid and dicrofenac were both less potent than indomethacin in producing gastric mucosal lesions at similar antiinflammatory doses. Mucosal PGE₂ content was abolished by the three compounds in the following doses (mg/kg): indomethacin (4 and 20); tiaprofenic acid (6 and 30); dicrofenac (20). Mucosal PGI₂ was maintained around 50% of the control value in rats given tiaprofenic acid in a dose of 6 mg/kg or dicrofenac in a dose of 4 mg/kg, while indomethacin in a dose of 4 mg/kg markedly reduced mucosal PGI₂ to 17% of the control value. In larger doses, tiaprofenic acid and dicrofenac were also significantly less potent in reducing mucosal PGI₂ than idomethacin. These results suggest that the difference in ulcerogenicity between idomethacin and the other two compounds was closely related to their potency in decreasing PGI₂ in the gastric (fundic) mucosa.     

Oxygen consumption,ventilation frequency and cytochrome c oxidase activity in blue cod (Parapercis colias) exposed to hydrogen sulphide or isoeugenol

The effects of hydrogen sulphide (H₂S) and isoeugenol exposure on activity, oxygen consumption (VO₂), ventilation frequency (Vf) and cytochrome c oxidase activity in a teleost fish are reported. In H₂S (200 µM Na₂S) exposed animals VO₂ and Vf decreased significantly (both to 40% of resting) after 30 min, concurrent with a loss of equilibrium and narcosis. Post-flushing, VO₂ increased to resting values, but Vf remained depressed (P < 0.05) until 30 min of recovery. Subsequently, equilibrium and mobility were regained accompanied by increases in VO₂ (66%) and Vf (15%) between 60–70 min of recovery. Isoeugenol (0.011 g L^− 1) exposed fish reached stage 4–5 of anaesthesia accompanied by decreases (P < 0.05) in VO₂ (64%) and Vf (38%) by 35 min. Post-flushing, VO₂ and Vf recovered to resting values, followed by a rise (P < 0.05) in VO₂ (45%) and Vf (25%). Overall, VO₂ in relation to the resting rate was reduced in isoeugenol treated animals. Conversely, VO₂ was increased (P < 0.05) relative to the resting rate in H₂S exposed fish. 20 and 200 µM Na₂S reduced cytochrome c oxidase activity (P < 0.05) in skeletal muscle and gill lamellae by between 69 and 97%, while isoeugenol had no effect in any tissue.     

Effects of intraperitoneal and intraventricular d-amphetamine administration on active avoidance performance in the rat

Intraventricular and intraperitoneal administration of d-amphetamine impaired asymptotic shuttle box avoidance performance in rats. Low ip doses (0.5, 1.0, 1.5, and 2.0 mg/kg) had no effect whereas higher ip doses (2.5, 3.0, 3.5, 4.0 mg/kg) impaired performance in a dose-related fashion. An inverted U-shaped function was obtained with the ivent doses; low dose (25 ug) and high doses (200 and 400 ug) impaired performance whereas intermediate doses (50 and 100 ug) had little effect. The cannulation procedure itself produced only minimal acquisition effects. The data tend to support the contention that amphetamine acts on the brain to cause the deterioration of well learned avoidance responding.     

NATURAL SELECTION ON THERMOGENIC CAPACITY OF HIGH-ALTITUDE DEER MICE

Adaptive explanations that rely on physiological arguments are common, but tests of hypotheses about the significance of whole-animal physiological performance (e.g., aerobic capacities) are rare. We studied phenotypic selection on the thermogenic capacity (i.e., maximal rate of oxygen consumption [VO₂max] elicited via cold exposure) of high-altitude (~3800 m) deer mice (Peromyscus maniculatus). A high VO₂max equates to a high capacity for heat production and should favor survival in the cold environments prevalent at high altitude. Strong directional selection favored high VO₂max, at least in one year. The selection for increased VO₂max is consistent with predictions derived from incorporating our physiological data into a biophysical model. During another year, we found weak evidence of selection for decreased body mass. Nonlinear selection was not significant for any of the selection episodes we studied. The strong directional selection for VO₂max that we observed suggests that—given ample genetic variation—aerobic metabolism and perhaps endothermy may have evolved rapidly on the geological time scale.     

Role of medial prefrontal cortex dopamine in age differences in response to amphetamine in rats: Locomotor activity after intra-mPFC injections of dopaminergic ligands

Changes in medial prefrontal cortex (mPFC) dopamine receptor expression and in mPFC projections to the nucleus accumbens in adolescence suggest that there may be age differences in the regulation of drug‐related behavior by the mPFC. The age‐specific role of prelimbic D1 dopamine receptors on amphetamine‐induced locomotor activity was investigated. In experiment 1, rats aged postnatal day 30 (P30), P45, and P75, corresponding to early and late adolescence and adulthood, were given an injection of D1 and D2 antagonists into the prelimbic mPFC before a systemic injection of 1.5 mg/kg of amphetamine and locomotor activity was recorded. In experiment 2, effects of intra‐prelimbic injections of a D1 agonist and antagonist on locomotor activity produced by a lower dose (0.5 mg/kg) of amphetamine were investigated. D2 receptor antagonist did not alter amphetamine‐induced activity, whereas the D1 receptor antagonist reduced activity produced by 1.5 mg/kg of amphetamine more in P30 than in P45 and P75 rats. In addition, D1 agonist enhanced the locomotor activating effects of 0.5 mg/kg of amphetamine in adolescent rats and decreased activity in adult rats. These results suggest that insufficient activation of mPFC D1 receptors may underlie the reduced activity at the low dose of amphetamine in early adolescent compared to adult rats. © 2011 Wiley Periodicals, Inc. Develop Neurobiol, 2012